On February 2, 2024, Zhejiang Anglikang Pharmaceutical Co., Ltd. (stock abbreviation: Anglikang, stock code: 002940) and Affinity(Shanghai) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Affinity") held the signing ceremony of the Strategic Cooperation Agreement in Anglikang’s headquarter building. Dr. Cheng Liu, Founder, CEO & Co-CMO of Affinity, Ji Ma, Chairman of Hongfu Investment, and Nanping Fang, Chairman of Anglikang, attended the event.  

Guogang Zheng, General Manager of Anglikang, mentioned during the signing ceremony: "Anglikang is a pharmaceutical company with a heritage of over 60 years, and Affinity is a world-leading biopharma focusing on Tumor Microenvironment-Activated technology platform. Anglikang is entering into innovative drugs development, and both parties share the same concept of developing innovative drugs to address the huge unmet clinical needs. We hope that through the strong alliance and technological complementation of the two companies, we can empower new energies into the development of China’s healthcare industry."

Dr. Cheng Liu, Founder, CEO & Co-CMO of Affinity, said: “The two parties have opened a new chapter of cooperation based on Affinity’s Tumor Microenvironment-Activated platform, and by leveraging each party’s advantages, we can accelerate the research and development process of innovative drugs and transform innovative results into applications faster, bringing in greater values to patients. It is based on this consensus that Affinity and Anglikang can work together to jointly promote innovative pharmaceutical products and contribute to the benefits of the whole society.”

Nanping Fang, Chairman of Anglikang, expressed his warm welcome to the arrival of Affinity and Hongfu Investment in witnessing this signing ceremony. Affinity granted a license to Anglikang for its QHL-1618 drug molecule, which will promote its clinical development. Hopefully two parties will establish a long-term strategic partnership based on close cooperation in the future, and continue to explore and expand into new areas of cooperation, and achieve a win-win development.

(Note: QHL-1618 uses small molecule compound as payload, and through Affinity’s unique linker technology and conditional activation in the tumor microenvironment, its efficacy and safety are greatly enhanced.)

About Anglikang 002940:

Zhejiang Anglikang Pharmaceutical Co., Ltd. is a modern pharmaceutical company engaging in APIs and pharmaceutical preparations, and featuring oral cephalosporins, cardiovascular and kidney diseases. The company was restructured and established in 2001, and after more than 20 years of development, it now has major production sites in Shengzhou in Zhejiang, Yancheng in Jiangsu, Shaoyang in Hunan, Sanming in Fujian, and Ji'an in Jiangxi. At present, the company owns more than 10 holding subsidiaries, and ranked among the top 200 pharmaceutical companies in China. It was listed on the Shenzhen Stock Exchange in October 2018.

About Affinity:

Affinity(Shanghai) Biopharmaceutical Co., Ltd. is a clinical-stage, oncology-focused biopharma developing next-generation, conditionally activated therapeutics based on Tumor MicroEnvironment Activated (TMEA) platform. Affinity was established in December 2011 and headquartered in Shanghai, China. It's a global originator, with 100% original pipeline and innovative drugs with global rights and proprietary protection. Its TMEA platform allows selective unleash of the active drug in the tumor microenvironment, solving “on target/ off tumor toxicity”, enhancing efficacy at targeted sites and dramatically improving the therapeutic index. At the same time, Affinity achieves a diversified platform pipeline through global technology licensing, accelerating the realization of innovative therapies and bringing values to patients and the whole society.